New Intelligent Automation Tech Significantly Cuts Clinical Trial Deployment Time

New intelligent automation technology applied across its clinical trials platform can cut standard trial build timelines by at least half, according to Medable Inc. The technology’s early application in electronic clinical outcomes assessment (eCOA) deployments—a major delay to study startup industry-wide—is significant. By automating laborious, manual tasks such as testing, Medable’s solution saves substantial time and removes eCOA from the critical path to trial go-live.
 
Medable claims its new artificial intelligence (AI) and automation capabilities catapult the company to the forefront of automating clinical trial operations and align with the industry’s perennial need to launch studies faster. Now, sponsors can eliminate common gridlocks caused by conversion, configuration, validation, and quality engineering. 
 
As part of a broader roadmap incorporating AI and intelligent automation, Medable’s updated eCOA capabilities include an auto-configuration tool that produces standard configurations, such as  assessment schedules, anchor dates, and patient flags, in minutes. Medable’s auto-validate tool also eliminates weeks of tedious testing to automatically deliver a downloadable Configuration Validation Report (CVR) that validates the quality of study builds.
 
“We are reimagining the way clinical trials are deployed by eliminating many of the biggest process bottlenecks,” Medable CEO/Co-Founder Michelle Longmire said. “Starting with eCOA, we are accelerating clinical trials while helping to improve data quality—ultimately enabling our vision of a one-day study startup to help deliver effective treatments and cures to patients faster. In 2024, expect to see more innovative technologies and new ways of delivering streamlined, patient-centric trials from Medable.”
 
Medable, which ranked in the top 8% of software companies on the 2023 Inc. 5000, has deployed its software-as-a-service platform in more than 300 decentralized and hybrid clinical trials in 60 countries, serving more than 1 million patients and research participants globally. Customers have achieved positive results—including 200 percent faster enrollment and 50% reduced costs. 
 
Medable’s digital clinical trials platform enhances speed, scale, and patient access in clinical research, accelerating medicines for thousands of conditions without treatment or cure. Named a Leader in the industry by Everest Group and awarded Best Digital Health Solution by the Galien Foundation, Medable is a privately held, venture-backed company headquartered in Palo Alto, Calif., and ranked No. 398 on the Inc. 5000 in 2023.